JP2024516264A5 - - Google Patents

Info

Publication number
JP2024516264A5
JP2024516264A5 JP2023566975A JP2023566975A JP2024516264A5 JP 2024516264 A5 JP2024516264 A5 JP 2024516264A5 JP 2023566975 A JP2023566975 A JP 2023566975A JP 2023566975 A JP2023566975 A JP 2023566975A JP 2024516264 A5 JP2024516264 A5 JP 2024516264A5
Authority
JP
Japan
Prior art keywords
formulation
content
mol
total mass
triblock copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516264A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/061511 external-priority patent/WO2022229402A1/en
Publication of JP2024516264A publication Critical patent/JP2024516264A/ja
Publication of JP2024516264A5 publication Critical patent/JP2024516264A5/ja
Pending legal-status Critical Current

Links

JP2023566975A 2021-04-30 2022-04-29 新規製剤 Pending JP2024516264A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305559 2021-04-30
EP21305559.3 2021-04-30
PCT/EP2022/061511 WO2022229402A1 (en) 2021-04-30 2022-04-29 New formulation

Publications (2)

Publication Number Publication Date
JP2024516264A JP2024516264A (ja) 2024-04-12
JP2024516264A5 true JP2024516264A5 (https=) 2025-04-16

Family

ID=75904839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566975A Pending JP2024516264A (ja) 2021-04-30 2022-04-29 新規製剤

Country Status (9)

Country Link
US (1) US20240325294A1 (https=)
EP (1) EP4329727A1 (https=)
JP (1) JP2024516264A (https=)
KR (1) KR20240006032A (https=)
CN (1) CN117222402A (https=)
AU (1) AU2022264844A1 (https=)
CA (1) CA3217538A1 (https=)
MX (1) MX2023012801A (https=)
WO (1) WO2022229402A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US9023897B2 (en) * 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
CN103446043B (zh) * 2012-05-29 2015-06-17 辽宁省计划生育科学研究院 一种原位凝胶注射植入剂
EP2866837B1 (en) * 2012-06-27 2022-12-14 Medincell S.A. Biodegradable drug delivery for hydrophobic compositions
US10188602B2 (en) * 2016-09-29 2019-01-29 Gesea Biosciences Inc. Bioerodible implant for long-term drug delivery and associated methods of manufacture and use
EP3655017B1 (en) * 2017-07-17 2025-01-22 Medincell S.A. Pharmaceutical composition
KR102441064B1 (ko) * 2017-07-17 2022-09-06 현대자동차주식회사 연료전지 차량의 제어 방법

Similar Documents

Publication Publication Date Title
US20220354956A1 (en) Biodegradable drug delivery for hydrophobic compositions
CA2381729C (en) Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof
CN103491946B (zh) 可生物降解的药物释放组合物
US7550157B2 (en) Method for the preparation of polymeric micelle via phase separation of block copolymer
EP1392254B1 (en) Micellar drug delivery systems for hydrophobic drugs
JP2015522001A5 (https=)
CN102933234A (zh) 可注射长效组合物的制备方法
JP2024516264A5 (https=)
AU2019221126B2 (en) Multi-use torasemide composition
CN101336892A (zh) 一种缓释拓扑酶抑制剂的凝胶注射剂及其制备方法
US20170281779A1 (en) Method of treating patients non-responsive to palonosetron
JP2024545690A (ja) 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法
AU2002249045A1 (en) Micellar drug delivery systems for hydrophobic drugs
HK1063742B (en) Micellar drug delivery systems for hydrophobic drugs